Results: In the WDT-UMP group, HBME-1 was positive in 6/14 (42.9 %) cases. CD56, a marker whose expression is reduced in thyroid carcinoma, showed a "malignant" profile (no expression) in 9/14 (64.3 %) cases. 6/14 (42.9 %) cases were positive for both antibodies. One case showed the coexpression of HBME-1, CD56, Galectin-3 and Cytokeratin-19. Only one FT-UMP case was positive for HBME-1. The follow-up data revealed no distant metastases or persistent disease.